1 / 19

November 19, 2013, Session CS.03 American Heart Association Scientific Sessions, Dallas, TX

Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-term Administration of AMG 145: 52-Week Results From the OSLER Study.

thy
Télécharger la présentation

November 19, 2013, Session CS.03 American Heart Association Scientific Sessions, Dallas, TX

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-term Administration of AMG 145: 52-Week Results From the OSLER Study Michael JKoren1, Robert P Giugliano2, Frederick Raal3, David Sullivan4, Michael Bolognese5, Gisle Langslet6, Fernando Civeira7, Ransi Somaratne8, Patric Nelson8, Thomas Liu8, Rob Scott8, Scott M Wasserman8, Marc S Sabatine2 for the OSLER Investigators 1Jacksonville Center for Clinical Research, Jacksonville, FL; 2TIMI Study Group/ Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA; 3Carbohydrate & Lipid Metabolism Research Unit, Division of Endocrinology & Metabolism, Department of Medicine, University of the Witwatersrand, Johannesburg, South Africa; 4Department of Clinical Biochemistry, Royal Prince Alfred Hospital, Camperdown, Australia; 5Bethesda Health Research Center, Bethesda, MD; 6Lipid Clinic, Oslo University Hospital, Oslo, Norway; 7Hospital Universitario Miguel Servet, Zaragoza, Spain; 8Amgen, Thousand Oaks, CA November 19, 2013, Session CS.03American Heart Association Scientific Sessions, Dallas, TX

  2. Background: PCSK9 Inhibition For LDL-C Reduction • PCSK9 inhibition has emerged as a new approach for treating hypercholesterolemia. • AMG 145 (Evolocumab), a fully human monoclonal antibody against PCSK9, reduced LDL-C by up to 65% and was well tolerated in 4 randomized, placebo-controlled, phase 2 clinical trials of 12 weeks duration in over 1300 hypercholesterolemic patients. 1-4 • Longer-term efficacy and safety of PCSK9 inhibition have not been reported to date. • Koren MJ, et al. Lancet. 2012;380:1995-2006 • Raal FJ, et al. Circulation. 2012;126:2408-2417 • Sullivan D, et al. JAMA. 2012;308:2497-2506 • Giugliano RP, et al. Lancet. 2012;380:2007-2017 PCSK9, Proprotein convertase subtilisin/kexin type 9

  3. The OSLER Trial • To provide longer-term data, patients completing any of the 4 phase 2 trials could participate in the Open-label Study of Long-tERm Evaluation Against LDL-C (OSLER) trial of evolocumab 420 mg Q4W + SOC or SOC alone. • OSLER is a global, multicenter, randomized, controlled, open-label extension trial. • We report the efficacy and safety results for 1104 hypercholesterolemic patients treated in OSLER for 1 year. Q4W, every 4 weeks; SOC, standard of care

  4. OSLER Study Design Year 1 Years 2–5 12-week studies: MENDEL (monotherapy) LAPLACE-TIMI 57 (patients on statins) GAUSS (statin intolerance) RUTHERFORD (Familial hyper-cholesterolemia) Standard of Care N = 368 Evolocumab + Standard of Care Randomization 2:1 End of Study Evolocumab +Standard of Care N = 736 Blinded Stabilization Period Unblinded Lipid Treatment Visits* 4 8 12 Q4W 52 Q4W End of parent study / Day 1 OSLER Week • Effects on LDL-C over 1 year • Safety and Tolerability Primary Objectives: Q4W, every 4 weeks. * Patients in the evolocumab + SOC group had in-person visits every 4 weeks. Patients in the SOC group had in-person visits at week 4, then every 3 months, with telephone visits every 4 weeks.

  5. OSLER: Baseline Patient Characteristics * Based on presence of angina, myocardial infarction, coronary artery bypass graft, or percutaneous coronary intervention, †Metabolic syndrome defined as 3 or more risk factors including elevated waist circumference, triglycerides ≥ 150 mg/dL, low HDL-C (< 40 mg/dL in men and < 50 mg/dL in women), hypertension, diabetes or fasting glucose ≥110 mg/dL. CAD, coronary artery disease; SD, standard deviation

  6. OSLER: Baseline Lipid Characteristics IQR, interquartile range; SD, standard deviation; UC, ultracentrifugation

  7. OSLER: Percentage Change in LDL-C, by UC, From Baseline to 1 Year -2% 10 0 -10 -3% -20 UC LDL-C Percentage Change from Baseline to Week 52, Mean (SE) -30 -52% -40 -50 -60 -52% Baseline Parent Study 12 24 36 48 52 Week 12 OSLER Study Week Not Evolocumab / Evolocumab + SOC (n = 192) Not Evolocumab / SOC Only (n = 96) Evolocumab / Evolocumab + SOC (n = 544) Evolocumab / SOC Only (n = 272) SE, standard error; SOC, standard of care; UC, ultracentrifugation

  8. OSLER: LDL-C Goal Achievement < 100 mg/dL Proportion of Patients, % Evolocumab + SOC < 70 mg/dL SOC Proportion of Patients, % LDL-C values by ultracentrifugation. SOC, standard of care

  9. OSLER: Effect of Evolocumab on Other Lipid Parameters at 1 Year Error bars represent standard error. Data in parentheses represent interquartile ranges. Week 52 vs baseline: * P < 0.0001; † P < 0.001; § P < 0.01; ‡ P < 0.05 Evolocumab vs placebo: § P< 0.0001; ¶ P< 0.001

  10. OSLER: Safety and Tolerability NA, not applicable; SOC, standard of care. *Percentage of adverse events. †Patients in the SOC group did not receive injections.

  11. OSLER: Key Laboratory Results SOC, standard of care. ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of normal

  12. OSLER: Adverse Events by Lowest Post-Baseline LDL-C Value AE, adverse event; SOC, standard of care. *In the SOC group, no patients had LDL-C <25 mg/dL, and 2 patients had LDL-C <50 mg/dL.

  13. OSLER: Nervous System/Psychiatric AEs By Lowest Post-Baseline LDL-C Value * In the SOC group, no patients had LDL-C <25 mg/dL, and 2 patients had LDL-C <50 mg/dL. † Includes “memory impairment” and “mental impairment” terms.

  14. OSLER: Musculoskeletal AEs AE, adverse event; SOC, standard of care. * In the SOC group, no patients had LDL-C <25 mg/dL, and 2 patients had LDL-C <50 mg/dL.

  15. OSLER: Laboratory Results by Lowest Post-Baseline LDL-C Value ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; SOC, standard of care; ULN, upper limit of normal. * In the SOC group, no patients had LDL-C <25 mg/dL, and 2 patients had LDL-C <50 mg/dL.

  16. OSLER: Adjudicated Cardiovascular Clinical Events SOC, standard of care

  17. OSLER: Conclusions • The 1 year OSLER analysis evaluated evolocumab in a diverse patient population in the largest and longest study of an anti-PCSK9 antibody reported to date. • Findings over > 1000 patient-years suggest a highly effective, consistent, and well tolerated therapy. • Evolocumab reduced LDL-C by an average of 50% beyond that achieved with optimal SOC in various hypercholesterolemic patient populations. • AE profile was generally balanced. • No adverse laboratory signals were observed. • No major increase in AEs was observed in patients who reached low or very low LDL-C levels.

  18. OSLER Study Thanks for your attention!

  19. Presenter Disclosure Information • Financial Disclosures: • Amgen Inc. funded this study. • M J Koren: employee of Jacksonville Center for Clinical Research, which has received research grants for PCSK9 studies from Amgen, Pfizer, Regeneron, Roche and Sanofi. • R P Giugliano: member of the TIMI Study Group, which received research grant support from Amgen for the conduct of the LAPLACE-TIMI 57 trial; honoraria for lectures and consultation from Amgen, Merck, Regeneron, and Sanofi-Aventis; research-grant support from Merck for work related to lipid-lowering therapies. • F. Raal: consulting fees from Amgen and Sanofi re: PCSK9 inhibitors; his institution, research funding re: PCSK9 inhibitor clinical trials from Amgen and Sanofi. • D Sullivan: research funding from Amgen, Abbott Products, AstraZeneca, Merck, Sharp and Dohme, and Sanofi Aventis; funding for educational programs from Abbott Products, AstraZeneca, Merck, Sharp, and Dohme, Pfizer Australia, and Roche; travel support from Merck, Sharp, and Dohme; advisory boards for Abbott Products, Merck, Sharp, and Dohme, and Pfizer Australia. • M Bolognese: research grants from Amgen, Unigene Laboratories Inc., Eli Lilly and Company, and Radius Health, Inc; speakers’ bureaus for Amgen, Eli Lilly and Company, and Genentech. • G Langslet: consultant/advisory board for Janssen Pharmaceuticals. • F Civeira: consulting/advisory fees from Amgen Inc. • M S Sabatine: member of the TIMI Study Group, which received research grant support from Amgen for the conduct of the LAPLACE-TIMI 57 trial; has received research-grant support through Brigham and Women’s Hospital from AstraZeneca/Bristol-Myers Squibb Alliance, Bristol-Myers Squibb/Sanofi-Aventis Joint Venture, Daiichi-Sanyo, Eisai, Genzyme, GlaxoSmithKline, Merck, Sanofi-Aventis, Takeda, Abbott Laboratories, Accumetrics, Critical Diagnostics, Nanosphere, and Roche Diagnostics; and has consulted for Aegerion, Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Intarcia, Merck, Pfizer, Sanofi-Aventis, AstraZeneca, and Vertex. • R Somaratne, P Nelson, T Liu, R Scott, and SM Wasserman: employees of Amgen who have received Amgen stock/stock options. • Unlabeled/unapproved uses disclosure: Evolocumab in patients with hyperlipidemia is investigational. • The authors acknowledge the editorial support of Meera Kodukulla, PhD, Amgen Inc., and Sue Hudson, BA, on behalf of Amgen Inc.

More Related